[go: up one dir, main page]

BRPI0312811A8 - monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica - Google Patents

monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica Download PDF

Info

Publication number
BRPI0312811A8
BRPI0312811A8 BRPI0312811A BR0312811A BRPI0312811A8 BR PI0312811 A8 BRPI0312811 A8 BR PI0312811A8 BR PI0312811 A BRPI0312811 A BR PI0312811A BR 0312811 A BR0312811 A BR 0312811A BR PI0312811 A8 BRPI0312811 A8 BR PI0312811A8
Authority
BR
Brazil
Prior art keywords
methyl
indolinone
anilino
pharmaceutical composition
piperazin
Prior art date
Application number
BRPI0312811A
Other languages
English (en)
Other versions
BR0312811A (pt
BRPI0312811B8 (pt
BRPI0312811B1 (pt
Inventor
Hilberg Frank
Jürgen Roth Gerald
Linz Günter
Sieger Peter
Bock Thomas
Rall Werner
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0312811(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0312811A publication Critical patent/BR0312811A/pt
Publication of BRPI0312811A8 publication Critical patent/BRPI0312811A8/pt
Publication of BRPI0312811B1 publication Critical patent/BRPI0312811B1/pt
Publication of BRPI0312811B8 publication Critical patent/BRPI0312811B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil-amino) anilino)-1-fenil-metilenoi-6-metóxi carbonil-2-indolinona e seu uso como uma composição farmacêutica". a presente invenção refere-se ao composto monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil amino) anilino)-1-fenil metileno]-6-metóxi carbonil-2-indolinona de fórmula (i) e seu uso como uma composição farmacêutica.
BRPI0312811A 2002-07-24 2003-07-18 monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica BRPI0312811B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10233500.1 2002-07-24
PCT/EP2003/007822 WO2004013099A1 (en) 2002-07-24 2003-07-18 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (4)

Publication Number Publication Date
BR0312811A BR0312811A (pt) 2005-04-19
BRPI0312811A8 true BRPI0312811A8 (pt) 2019-01-02
BRPI0312811B1 BRPI0312811B1 (pt) 2019-03-12
BRPI0312811B8 BRPI0312811B8 (pt) 2021-05-25

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312811A BRPI0312811B8 (pt) 2002-07-24 2003-07-18 monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica

Country Status (35)

Country Link
US (2) US7119093B2 (pt)
EP (2) EP2386543A1 (pt)
JP (1) JP5039279B2 (pt)
KR (1) KR101145691B1 (pt)
CN (1) CN100351235C (pt)
AR (2) AR040662A1 (pt)
AT (1) ATE551322T1 (pt)
AU (1) AU2003254376B2 (pt)
BR (1) BRPI0312811B8 (pt)
CA (1) CA2493310C (pt)
CY (1) CY1112916T1 (pt)
DE (1) DE10233500A1 (pt)
DK (1) DK1527047T3 (pt)
EA (1) EA008684B1 (pt)
EC (1) ECSP055571A (pt)
EG (1) EG24562A (pt)
ES (1) ES2384968T3 (pt)
HR (1) HRP20050070B1 (pt)
IL (2) IL166405A0 (pt)
ME (1) ME00353B (pt)
MX (1) MXPA04012785A (pt)
MY (1) MY136883A (pt)
NO (1) NO330486B1 (pt)
NZ (1) NZ538367A (pt)
PE (1) PE20040704A1 (pt)
PL (1) PL223758B1 (pt)
PT (1) PT1527047E (pt)
RS (1) RS52283B (pt)
SA (1) SA03240446B1 (pt)
SI (1) SI1527047T1 (pt)
TW (1) TWI285635B (pt)
UA (1) UA78352C2 (pt)
UY (1) UY27904A1 (pt)
WO (1) WO2004013099A1 (pt)
ZA (1) ZA200409814B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
DK2985025T3 (en) 2008-06-06 2018-03-19 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429527A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of cancer and fibrotic diseases
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
WO2017178428A1 (en) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
WO2017198202A1 (zh) * 2016-05-19 2017-11-23 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
JP2019522638A (ja) 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
US10772885B2 (en) 2016-09-26 2020-09-15 Reyoung (Suzhou) Biology Science & Technology Co., Ltd. Composition for treating ocular diseases and methods of usage and making
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
US10981896B2 (en) * 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
WO2018165865A1 (zh) * 2017-03-14 2018-09-20 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited Process for the preparation of nintedanib
FI3700529T3 (fi) 2017-10-23 2025-09-18 Boehringer Ingelheim Int Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
CA3093225A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
WO2020041631A1 (en) 2018-08-22 2020-02-27 Avalyn Pharma Inc. Specially formulated compositions of inhaled nintedanib and nintedanib salts
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
WO2021236935A1 (en) 2020-05-22 2021-11-25 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
WO2022029805A1 (en) * 2020-08-07 2022-02-10 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN119630395A (zh) 2022-02-28 2025-03-14 努福米克斯技术有限公司 用于治疗特发性肺纤维化的组合物和方法
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate
KR20250118711A (ko) 2024-01-30 2025-08-06 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제
WO2025261988A1 (fr) 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
BR0013498A (pt) * 1999-08-23 2002-05-14 Solvay Pharm Bv Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CY1112916T1 (el) 2016-04-13
AU2003254376A1 (en) 2004-02-23
CA2493310C (en) 2011-01-18
PE20040704A1 (es) 2004-11-29
HRP20050070B1 (hr) 2013-09-30
IL166405A0 (en) 2006-01-15
NZ538367A (en) 2008-01-31
EA200500146A1 (ru) 2005-08-25
EP1527047B1 (en) 2012-03-28
ME00353B (me) 2011-10-10
PT1527047E (pt) 2012-06-28
HRP20050070A2 (en) 2005-12-31
DK1527047T3 (da) 2012-07-16
CN1671660A (zh) 2005-09-21
BR0312811A (pt) 2005-04-19
TW200409754A (en) 2004-06-16
CN100351235C (zh) 2007-11-28
SA03240446B1 (ar) 2007-07-31
AR094217A2 (es) 2015-07-15
ZA200409814B (en) 2006-02-22
KR20050042139A (ko) 2005-05-04
US20060258681A1 (en) 2006-11-16
TWI285635B (en) 2007-08-21
AU2003254376B2 (en) 2010-06-17
RS20050046A (sr) 2007-09-21
US20040176392A1 (en) 2004-09-09
AR040662A1 (es) 2005-04-13
KR101145691B1 (ko) 2012-05-25
ES2384968T3 (es) 2012-07-16
ECSP055571A (es) 2005-04-18
BRPI0312811B8 (pt) 2021-05-25
NO20050985L (no) 2005-02-23
RS52283B (sr) 2012-10-31
SI1527047T1 (sl) 2012-07-31
NO330486B1 (no) 2011-04-26
BRPI0312811B1 (pt) 2019-03-12
UY27904A1 (es) 2004-02-27
HK1078851A1 (zh) 2006-03-24
UA78352C2 (uk) 2007-03-15
MEP53708A (en) 2011-05-10
EP2386543A1 (en) 2011-11-16
PL372996A1 (en) 2005-08-08
WO2004013099A1 (en) 2004-02-12
EP1527047A1 (en) 2005-05-04
ATE551322T1 (de) 2012-04-15
CA2493310A1 (en) 2004-02-12
US7119093B2 (en) 2006-10-10
EG24562A (en) 2009-10-25
PL223758B1 (pl) 2016-10-31
MXPA04012785A (es) 2005-06-08
EA008684B1 (ru) 2007-06-29
IL166405A (en) 2009-11-18
JP2005535684A (ja) 2005-11-24
MY136883A (en) 2008-11-28
DE10233500A1 (de) 2004-02-19
JP5039279B2 (ja) 2012-10-03

Similar Documents

Publication Publication Date Title
BRPI0312811A8 (pt) monoetano sulfonato de 3-z-[1-(4-(n-((4-metil-piperazin-1-il)metilcarbonil)-n-metil-amino)anilino)-1-fenilmetileno]-6-metóxicarbonil-2-indolinona, seu uso, e composição farmacêutica
PE20040647A1 (es) Inhibidores de cinasas de tirosina
ATE333453T1 (de) Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
TW200700396A (en) Pyrazine-2-carboxamide derivatives as mglur5 antagonists
ATE342265T1 (de) Neue prodrugs von 1-methyl-2-(4- amidinophenylaminomethyl)-benzimidazol-5-yl- carbonsäure-(n -2-pyridil-n-2- hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE391715T1 (de) Heterozyklische mutilinester und deren verwendung als bakterizide
TW200722424A (en) Substituted piperidines
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
DE60202669D1 (de) 6-phenylbenzonaphthyidine
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
HRP20090143T3 (hr) N-oksidi kao predlijekovi derivata piperazina i piperidina
EA200501299A1 (ru) Замещенные производные анилина
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
EA200501499A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ п-ДИАМИНОБЕНЗОЛА
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
TH100980B (th) 3-z-[1-(4-(n-((4-เมทิล-ไพเพอราซิน-1-อิล)-เมทิลคาร์บอนิล)-n-เมทิล-อะมิโน)-แอนิลิโน)-1-เฟนิล-เมทิลีน]-6-เมทอกซีคาร์บอนิล-2-อินโคลิโนน-โมโนอีเทนซัลโฟเนต และการใช้สารนั้นเป็นสารผสมทางเภสัชกรรม
DE60200935D1 (de) Diazocinderivate und deren verwendung als tryptase inhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.012371/2021-48 ORIGEM: JUIZO FEDERAL DA 31A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5126121-81.2021.4.02.5101 NULIDADE DE PATENTE DE INVENCAO AUTOR: SUN FARMACEUTICA DO BRASIL LTDA REU(S): BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG E BOEHRINGER INGELHEIM INTERNATIONAL GMBH E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI